← Back to Search

TheraSphere for Liver Cancer (STOP-HCC Trial)

N/A
Waitlist Available
Led By Riad Salem, MD, MBA
Research Sponsored by Boston Scientific Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from time of randomization up to date of death or last date known to be alive (data cut-off 30apr2022), an average of 16.3 months
Awards & highlights

STOP-HCC Trial Summary

This study is evaluating whether a drug called TheraSphere can improve the survival of people with liver cancer.

Eligible Conditions
  • Liver Cancer

STOP-HCC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from time of randomization up to date of death or last date known to be alive (data cut-off 30apr2022), an average of 16.3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from time of randomization up to date of death or last date known to be alive (data cut-off 30apr2022), an average of 16.3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Survival (OS) Per Protocol (PP) Population
Overall Survival (OS) Results Are Based on the Modified Intent-to-treat (mITT)
Secondary outcome measures
Time to Progression (TTP) From Time of Randomization Based on Investigator, According RECIST Criteria.
Time to Untreatable Progression (TTUP) From the Time of Randomization Based One or More of the Following: Investigator Assessment According to RECIST Criteria
Tumor Response

STOP-HCC Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment groupExperimental Treatment1 Intervention
Standard-of-care sorafenib plus TheraSphere
Group II: Control groupActive Control1 Intervention
Standard-of-care sorafenib, with no added therapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TheraSphere
2007
Completed Early Phase 1
~2150

Find a Location

Who is running the clinical trial?

Boston Scientific CorporationLead Sponsor
720 Previous Clinical Trials
932,496 Total Patients Enrolled
3 Trials studying Liver Cancer
474 Patients Enrolled for Liver Cancer
Biocompatibles UK LtdIndustry Sponsor
24 Previous Clinical Trials
2,003 Total Patients Enrolled
2 Trials studying Liver Cancer
95 Patients Enrolled for Liver Cancer
Riad Salem, MD, MBAPrincipal InvestigatorDept of Radiology Northwestern University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
2012. "Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01556490.
~40 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top